PharmAla Biotech forms joint venture for APA-01 drug development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
May 13, 2026 8:30 AM EDTTORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (PharmAla or the Company), a leader in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX-class compounds, today announced that it has executed a definitive SPV Formation, Shareholder and License Agreement (the Definitive Agreement) with Aluvaris Inc. (Aluvaris) and Diteba Inc. (Diteba). The Definitive Agreement establishes a jointly-owned special purpose vehicle called Restora Neurosciences (the Restora or the... More
